Novo Nordisk’s (NVO) approved drug Rybelsus awaits the FDA decision for an indication to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke, or death in adults with type 2 diabetes and established cardiovascular disease on January 20, 2020.Rybelsus, the first oral glucagon-like peptide-1 (GLP-1) receptor agonist, received its initial approval in September 2019, for the treatment of adults with type 2 diabetes mellitus. The drug is approved for use in two therapeutic dosages, 7 mg and 14 mg as an adjunct to diet and exercise, and sports a boxed warning about the potential increased risk of thyroid c-cell tumors.Priced at $26 per day, or $772 per 30 tablets, Rybelsus is expected to generate annual sales in excess of $2 billion by 2024.NVO closed Monday’s (Dec.30, 2019) trading at $57.73, down 0.91%.